Cell
AssigneeAntion Biosciences SA
InventorsMarco ALESSANDRINI, Antonija ŠAKIC, Audrey ROUSSEL-GERVAIS, Inès LANZ, Sten ILMJÄRV
Life of this patent
Estimating the term…
Abstract
The present invention relates to donor cells that are engineered for use in universal donor cell therapies, for allogeneic, off-the-shelf administration, and that possess improved persistence in the immune system of a host. The present invention also relates to the use of miRNA expression constructs in such engineered donor cells.
Claims84
An engineered donor cell with reduced rejection by the immune system of a host, wherein one or more cell surface-expressed polypeptides involved in immune signalling are functionally modulated.
A miRNA expression construct comprising one or more miRNA hairpins targeting B2M, NLRC5, RFX5, RFXANK, RFXAP, CIITA, TCRa, TCRb, CD3d, CD3g, CD3e and/or CD3z;
- optionally wherein the construct further comprises an expressed transcript.
Dependencies are inferred from the claim text.